Organogenesis Q1 Earnings Miss Expectations with Significant Revenue Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy ORGO?
Source: seekingalpha
- Disappointing Earnings: Organogenesis reported a Q1 GAAP EPS of -$0.44, missing expectations by $0.13, indicating significant challenges in profitability amidst a tough market environment.
- Substantial Revenue Decline: The total revenue for Q1 was $37.2M, reflecting a 57.1% year-over-year decrease and falling short of expectations by $6.1M, highlighting weakened market demand and intensified competition.
- Divergent Product Line Performance: Net revenue from Advanced Wound Care products was $29.5M, down 63% year-over-year, while Surgical & Sports Medicine products maintained $6.8M, indicating varied market performance across product lines.
- Pessimistic Future Outlook: The company now expects total net revenue for 2026 to range between $270M and $310M, significantly below the consensus of $401.2M, suggesting ongoing market pressures will hinder recovery efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORGO
Wall Street analysts forecast ORGO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.370
Low
9.00
Averages
9.00
High
9.00
Current: 2.370
Low
9.00
Averages
9.00
High
9.00
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organogenesis Holdings Reports Q1 2026 Earnings with Significant Revenue Decline
- Significant Revenue Decline: Organogenesis reported net revenue of $36.3 million for Q1 2026, reflecting a 58% year-over-year decline primarily due to a 63% drop in Advanced Wound Care product sales, indicating severe impacts on the company's market competitiveness.
- Restructuring Measures Implemented: In response to declining revenue expectations, the company undertook a restructuring in March, reducing its workforce by 88 employees and closing its St. Petersburg, Florida facility, which is expected to yield annual cost savings of approximately $14 million, aimed at enhancing financial stability.
- Deteriorating Profitability: The GAAP net loss for the first quarter was $53.2 million, with an adjusted EBITDA loss of $48.2 million, and gross margin plummeted to 29% from 73% last year, reflecting challenges in inventory management and product mix.
- Cautious Future Outlook: The company expects total net revenue for 2026 to range between $270 million and $310 million, representing a year-over-year decline of 45% to 52%, and while management remains optimistic about sequential revenue growth in the second half, there is increased uncertainty regarding the timing of CMS policy clarifications.
See More
Organogenesis Q1 Earnings Miss Expectations with Significant Revenue Decline
- Disappointing Earnings: Organogenesis reported a Q1 GAAP EPS of -$0.44, missing expectations by $0.13, indicating significant challenges in profitability amidst a tough market environment.
- Substantial Revenue Decline: The total revenue for Q1 was $37.2M, reflecting a 57.1% year-over-year decrease and falling short of expectations by $6.1M, highlighting weakened market demand and intensified competition.
- Divergent Product Line Performance: Net revenue from Advanced Wound Care products was $29.5M, down 63% year-over-year, while Surgical & Sports Medicine products maintained $6.8M, indicating varied market performance across product lines.
- Pessimistic Future Outlook: The company now expects total net revenue for 2026 to range between $270M and $310M, significantly below the consensus of $401.2M, suggesting ongoing market pressures will hinder recovery efforts.
See More
Organogenesis Completes BLA Submission for ReNu Therapy
- Regulatory Milestone: Organogenesis Holdings Inc. has completed its rolling BLA submission for ReNu, marking a significant regulatory milestone for a therapy aimed at millions suffering from chronic knee pain.
- Patient Impact: Knee osteoarthritis currently affects approximately 31.1 million Americans, with projections indicating an increase to 34.4 million by 2027, highlighting the therapy's potential importance in improving patient quality of life.
- Clinical Trial Results: ReNu has been evaluated in three large randomized controlled trials involving over 1,300 patients and received FDA RMAT designation in 2021, underscoring its efficacy and safety in treating knee osteoarthritis.
- Market Performance: ORGO stock has traded between $2.21 and $7.07 over the past year, closing at $2.40, reflecting market confidence in the company's future developments.
See More
Organogenesis Completes BLA Submission for ReNu® Allograft
- BLA Submission Completed: Organogenesis has completed the Biologics License Application (BLA) submission for ReNu®, a product aimed at treating knee osteoarthritis, marking a significant milestone in the regenerative medicine sector and expected to greatly enhance patient treatment options.
- Significant Market Potential: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, highlighting the strategic importance of ReNu® in addressing the growing market demand and potentially generating substantial revenue growth for the company.
- Clinical Research Backing: ReNu® has been studied in three large randomized controlled trials involving over 1,300 patients and received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation in 2021, further strengthening its market competitiveness and regulatory recognition.
- Positive Regulatory Engagement: Organogenesis reports productive discussions with the FDA regarding regulatory engagement, which lays a solid foundation for the future approval and commercialization of ReNu®, potentially accelerating its market launch.
See More
Organogenesis Completes PuraPly AM Clinical Trial for Diabetic Foot Ulcers
- Clinical Trial Success: Organogenesis has completed a randomized controlled trial for PuraPly AM in managing non-healing diabetic foot ulcers, achieving significant wound healing improvements compared to standard care, thereby supporting its application in advanced wound management.
- Product Differentiation: PuraPly AM combines a native cross-linked collagen matrix with the antimicrobial PHMB, creating a dual mechanism that effectively manages bioburden while promoting healing, enhancing its competitive edge among skin substitutes.
- Future Trial Plans: This success paves the way for PuraPly AM to advance into two large Phase 3 trials, further solidifying its potential for broader clinical adoption and driving the company's strategic growth in wound management.
- Financial Outlook: Organogenesis projects total net revenue for fiscal year 2026 to range between $350 million and $420 million, reflecting a decline of approximately 25% to 38% compared to $564.2 million in net revenue for full year 2025, indicating market challenges and necessary adjustments.
See More
Organogenesis Shares Surge 29% After Successful Clinical Trial for PuraPlyAM
- Successful Clinical Trial: Organogenesis's PuraPlyAM achieved its primary endpoint in a randomized controlled trial involving 170 patients, demonstrating statistically significant wound closure compared to standard care alone, highlighting its potential in treating diabetic foot ulcers.
- Positive Market Reaction: This announcement led to a ~29% surge in Organogenesis shares during premarket trading, reflecting increased investor confidence in the company's future prospects in regenerative medicine, which may attract more attention to its product line.
- Future Development Plans: The company intends to publish trial results in a peer-reviewed journal soon, a move that could enhance PuraPlyAM's market recognition and potentially support its inclusion in insurance coverage policies, thereby expanding its market share.
- Financial Outlook Challenges: Despite the successful clinical trial, Organogenesis faces a projected revenue decline of 25%-38% in 2026 due to CMS policy changes, indicating the company's vulnerability in a shifting market environment.
See More
Organogenesis Holdings Reports Q1 2026 Earnings with Significant Revenue Decline
- Significant Revenue Decline: Organogenesis reported net revenue of $36.3 million for Q1 2026, reflecting a 58% year-over-year decline primarily due to a 63% drop in Advanced Wound Care product sales, indicating severe impacts on the company's market competitiveness.
- Restructuring Measures Implemented: In response to declining revenue expectations, the company undertook a restructuring in March, reducing its workforce by 88 employees and closing its St. Petersburg, Florida facility, which is expected to yield annual cost savings of approximately $14 million, aimed at enhancing financial stability.
- Deteriorating Profitability: The GAAP net loss for the first quarter was $53.2 million, with an adjusted EBITDA loss of $48.2 million, and gross margin plummeted to 29% from 73% last year, reflecting challenges in inventory management and product mix.
- Cautious Future Outlook: The company expects total net revenue for 2026 to range between $270 million and $310 million, representing a year-over-year decline of 45% to 52%, and while management remains optimistic about sequential revenue growth in the second half, there is increased uncertainty regarding the timing of CMS policy clarifications.
See More
Organogenesis Q1 Earnings Miss Expectations with Significant Revenue Decline
- Disappointing Earnings: Organogenesis reported a Q1 GAAP EPS of -$0.44, missing expectations by $0.13, indicating significant challenges in profitability amidst a tough market environment.
- Substantial Revenue Decline: The total revenue for Q1 was $37.2M, reflecting a 57.1% year-over-year decrease and falling short of expectations by $6.1M, highlighting weakened market demand and intensified competition.
- Divergent Product Line Performance: Net revenue from Advanced Wound Care products was $29.5M, down 63% year-over-year, while Surgical & Sports Medicine products maintained $6.8M, indicating varied market performance across product lines.
- Pessimistic Future Outlook: The company now expects total net revenue for 2026 to range between $270M and $310M, significantly below the consensus of $401.2M, suggesting ongoing market pressures will hinder recovery efforts.
See More
Organogenesis Completes BLA Submission for ReNu Therapy
- Regulatory Milestone: Organogenesis Holdings Inc. has completed its rolling BLA submission for ReNu, marking a significant regulatory milestone for a therapy aimed at millions suffering from chronic knee pain.
- Patient Impact: Knee osteoarthritis currently affects approximately 31.1 million Americans, with projections indicating an increase to 34.4 million by 2027, highlighting the therapy's potential importance in improving patient quality of life.
- Clinical Trial Results: ReNu has been evaluated in three large randomized controlled trials involving over 1,300 patients and received FDA RMAT designation in 2021, underscoring its efficacy and safety in treating knee osteoarthritis.
- Market Performance: ORGO stock has traded between $2.21 and $7.07 over the past year, closing at $2.40, reflecting market confidence in the company's future developments.
See More
Organogenesis Completes BLA Submission for ReNu® Allograft
- BLA Submission Completed: Organogenesis has completed the Biologics License Application (BLA) submission for ReNu®, a product aimed at treating knee osteoarthritis, marking a significant milestone in the regenerative medicine sector and expected to greatly enhance patient treatment options.
- Significant Market Potential: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, highlighting the strategic importance of ReNu® in addressing the growing market demand and potentially generating substantial revenue growth for the company.
- Clinical Research Backing: ReNu® has been studied in three large randomized controlled trials involving over 1,300 patients and received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation in 2021, further strengthening its market competitiveness and regulatory recognition.
- Positive Regulatory Engagement: Organogenesis reports productive discussions with the FDA regarding regulatory engagement, which lays a solid foundation for the future approval and commercialization of ReNu®, potentially accelerating its market launch.
See More
Organogenesis Completes PuraPly AM Clinical Trial for Diabetic Foot Ulcers
- Clinical Trial Success: Organogenesis has completed a randomized controlled trial for PuraPly AM in managing non-healing diabetic foot ulcers, achieving significant wound healing improvements compared to standard care, thereby supporting its application in advanced wound management.
- Product Differentiation: PuraPly AM combines a native cross-linked collagen matrix with the antimicrobial PHMB, creating a dual mechanism that effectively manages bioburden while promoting healing, enhancing its competitive edge among skin substitutes.
- Future Trial Plans: This success paves the way for PuraPly AM to advance into two large Phase 3 trials, further solidifying its potential for broader clinical adoption and driving the company's strategic growth in wound management.
- Financial Outlook: Organogenesis projects total net revenue for fiscal year 2026 to range between $350 million and $420 million, reflecting a decline of approximately 25% to 38% compared to $564.2 million in net revenue for full year 2025, indicating market challenges and necessary adjustments.
See More
Organogenesis Shares Surge 29% After Successful Clinical Trial for PuraPlyAM
- Successful Clinical Trial: Organogenesis's PuraPlyAM achieved its primary endpoint in a randomized controlled trial involving 170 patients, demonstrating statistically significant wound closure compared to standard care alone, highlighting its potential in treating diabetic foot ulcers.
- Positive Market Reaction: This announcement led to a ~29% surge in Organogenesis shares during premarket trading, reflecting increased investor confidence in the company's future prospects in regenerative medicine, which may attract more attention to its product line.
- Future Development Plans: The company intends to publish trial results in a peer-reviewed journal soon, a move that could enhance PuraPlyAM's market recognition and potentially support its inclusion in insurance coverage policies, thereby expanding its market share.
- Financial Outlook Challenges: Despite the successful clinical trial, Organogenesis faces a projected revenue decline of 25%-38% in 2026 due to CMS policy changes, indicating the company's vulnerability in a shifting market environment.
See More
